BioMarin Pharmaceutical-BioMarin is Buying a Rare-Disease Biotech for Nearly $5 Billion. The Stock Is Jumping.

BioMarin is Buying a Rare-Disease Biotech for Nearly $5 Billion. The Stock Is Jumping.

公司战略与产品组合 - 公司于2025年进行了第二次收购 [1] - 此次收购旨在实现产品组合的多元化 [1] - 收购背景源于其A型血友病基因疗法在商业上的失败 [1]